Issue 90, 2025

A glutathione-activated programmable DNA device for visual microRNA-210-enhanced photodynamic therapy of hypoxic lung cancer

Abstract

In this study, we construct a glutathione (GSH)-activated DNA nanodevice conjugated to a porphyrin-based metal–organic framework (PCN-224), creating an integrated theranostic platform for modulating hypoxia, enabling miRNA-210-specific imaging and enhancing photodynamic therapy (PDT).

Graphical abstract: A glutathione-activated programmable DNA device for visual microRNA-210-enhanced photodynamic therapy of hypoxic lung cancer

Supplementary files

Article information

Article type
Communication
Submitted
09 Sep 2025
Accepted
29 Sep 2025
First published
15 Oct 2025

Chem. Commun., 2025,61, 17681-17684

A glutathione-activated programmable DNA device for visual microRNA-210-enhanced photodynamic therapy of hypoxic lung cancer

X. Meng, S. Sun, X. Zhang and H. Dong, Chem. Commun., 2025, 61, 17681 DOI: 10.1039/D5CC05182G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements